We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+10.4%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$3.08B
AUM Growth
+$170M
Cap. Flow
-$43.5M
Cap. Flow %
-1.41%
Top 10 Hldgs %
31.64%
Holding
198
New
2
Increased
42
Reduced
41
Closed
9

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$41.2M
2
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$21.9M
3
UTHR icon
United Therapeutics
UTHR
+$14.5M
4
TMO icon
Thermo Fisher Scientific
TMO
+$12.5M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$11.5M

Top Sells

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$21.8M
2
STE icon
Steris
STE
+$20M
3
ILMN icon
Illumina
ILMN
+$18.6M
4
WAT icon
Waters Corp
WAT
+$17.2M
5
BMY icon
Bristol-Myers Squibb
BMY
+$15.4M

Sector Composition

Rank Sector Weight
1 Healthcare 95.67%
2 Real Estate 2.94%
3 Industrials 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRBP icon
176
Corbus Pharmaceuticals
CRBP
$166M
$757K 0.02%
13,783
– –
GMDA
177
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$757K 0.02%
118,142
– –
CHCT
178
Community Healthcare Trust
CHCT
$526M
$707K 0.02%
14,900
– –
UHT
179
Universal Health Realty Income Trust
UHT
$604M
$693K 0.02%
11,258
– –
NHI icon
180
National Health Investors
NHI
$3.7B
$673K 0.02%
10,038
– –
ASRT
181
DELISTED
Assertio
ASRT
$640K 0.02%
27,372
– –
YARW
182
Yarrow Bioscience, Inc. Common Stock
YARW
$23.4M
$475K 0.02%
150
– –
SPPI
183
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$430K 0.01%
114,670
– –
CBAY
184
DELISTED
Cymabay Therapeutics
CBAY
$384K 0.01%
88,102
– –
CLDX icon
185
Celldex Therapeutics
CLDX
$2.94B
$236K 0.01%
7,053
– –
ALR
186
DELISTED
AlerisLife Inc
ALR
$140K ﹤0.01%
24,237
– –
ORKA
187
Oruka Therapeutics
ORKA
$5.77B
$113K ﹤0.01%
2,705
– –
BLCM
188
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$20K ﹤0.01%
6,000
– –
ALKS icon
189
Alkermes
ALKS
$8.23B
– –
-169,930
Closed -$3.17M
CLLS
190
Cellectis
CLLS
$278M
– –
-11,955
Closed -$242K
CLSD
191
DELISTED
Clearside Biomedical
CLSD
– –
-11,022
Closed -$408K
GMAB icon
192
Genmab
GMAB
$17.7B
– –
-73,015
Closed -$2.4M
HRTX icon
193
Heron Therapeutics
HRTX
$93.5M
– –
-131,183
Closed -$2.13M
TDOC icon
194
Teladoc Health
TDOC
$1.23B
– –
-29,664
Closed -$5.39M
THC icon
195
Tenet Healthcare
THC
$20.3B
– –
-60,336
Closed -$3.14M
PVLA
196
Palvella Therapeutics
PVLA
$2.04B
– –
-12,792
Closed -$2.63M
MORF
197
DELISTED
Morphic Holding, Inc. Common Stock
MORF
– –
-89,559
Closed -$5.67M
4 5 6 7
8

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, Tekla Capital Management held 198 positions worth $3.08B, up 5.9% from $2.91B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Tekla Capital Management's Q2 2021 filing shows 2 new, 42 increased, 41 reduced and 9 closed positions. Its largest new stake was VectivBio Holding AG Ordinary Shares: 145,000 shares worth $1.69M. The largest sale was Elevance Health, an estimated $21.8M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q2 2021 buy was VectivBio Holding AG Ordinary Shares: 145,000 shares worth $1.69M.
  • Tekla Capital Management added most to UnitedHealth in Q2 2021, an estimated $41.2M increase.
  • Tekla Capital Management's biggest Q2 2021 reduction was Elevance Health, cutting an estimated $21.8M.
  • Tekla Capital Management fully exited Morphic Holding, Inc. Common Stock in Q2 2021, selling an estimated $5.67M.
  • Tekla Capital Management's ten largest holdings make up 32% of its $3.08B portfolio in Q2 2021.
  • Tekla Capital Management opened 2 new positions and closed 9 in Q2 2021.
  • Tekla Capital Management's portfolio value rose 5.9% quarter-over-quarter to $3.08B.

Based on Tekla Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.